Q-omics provides the consensus-scored PRR14 profile across patient tissues and cancer cell-line models. PRR14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRR14 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, PRR14 protein abundance shows 20,188 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRP, and LUAD as cancer lineages where PRR14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR14 survival associations across molecular data types. PRR14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR14 RNA expression–survival associations across cancer types. High PRR14 expression shows unfavorable associations in ACC, LIHC and UCS, but favorable associations in COAD, ESCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRR14 RNA expression.
This table summarizes PRR14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PRR14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR14 shows lower tumor expression in KICH and higher tumor expression in KIRP, KIRC, COAD, LIHC and HNSC. The KIRP box plot shows higher PRR14 RNA expression in tumor versus normal tissue (log2 FC = +1.529, t-test p < 0.001).
This table shows molecular features associated with PRR14 in patient tissues and cancer cell lines. In patient samples, PRR14 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
